Melevodopa/carbidopa

Melevodopa/carbidopa

Melevodopa
Carbidopa
Combination of
Melevodopa	Dopamine receptor agonist
Carbidopa	Aromatic L-amino acid decarboxylase inhibitor
Clinical data
Trade names	Sirio
Other names	Carbidopa/melevodopa; Levodopa methyl ester/carbidopa; CHF-1512; CHF1512; CNP-1512; CNP1512; GT-1512; GT1512; V-1512; V1512
Routes of administration	Oral[1]

Melevodopa/carbidopa, sold under the brand name Sirio, is a combination of melevodopa, a prodrug of the dopamine precursor and hence non-selective dopamine receptor agonist levodopa (L-DOPA), and carbidopa, a peripherally selective aromatic L-amino acid decarboxylase (AAAD) inhibitor, which is used in the treatment of Parkinson's disease in Italy.^{[2][3][4][5][1]} It is taken orally in the form of tablets.^[1][4]

See also

• Levodopa/carbidopa
• Foscarbidopa/foslevodopa
• Levodopa/carbidopa/entacapone
• Levodopa/benserazide

References

1. "Melevodopa: Uses, Interactions, Mechanism of Action". DrugBank Online. 1 April 2015. Retrieved 27 September 2024.
2. "Melevodopa/carbidopa". AdisInsight. Springer Nature Switzerland AG. 23 September 2021. Retrieved 27 September 2024.
3. Stocchi F, Marconi S (July 2010). "Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio)". Clinical Neuropharmacology. 33 (4): 198–203. doi:10.1097/WNF.0b013e3181de8924. PMID 20414107.
4. Antonini A, Chaudhuri KR, Martinez-Martin P, Odin P (February 2010). "Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease". CNS Drugs. 24 (2): 119–129. doi:10.2165/11310940-000000000-00000. PMID 20088619.
5. Hengartner D, Fernandez HH (February 2019). "The next chapter in symptomatic Parkinson disease treatments". Parkinsonism & Related Disorders. 59: 39–48. doi:10.1016/j.parkreldis.2019.01.002. PMID 30661840.